Obviousness

Obviousness Analysis under 35 U.S.C. § 103 for US12221638

This analysis considers the obviousness of US Patent 12221638 under 35 U.S.C. § 103, based on the prior art references explicitly cited within the patent text. The core invention relates to a method for producing recombinant hyaluronidase PH20 or variants with improved enzymatic activity and productivity by controlling N-glycan levels through specific cell culture conditions.

Identification of Key Prior Art Teachings

The patent itself identifies several relevant pieces of prior art and the problems they address:

1. Recombinant Hyaluronidase PH20 and its Importance: Recombinant human PH20 protein, active at neutral pH, was developed by Halozyme Therapeutics Inc. and sold as "Hylenex" (Bookbinder et al., 2006). This establishes the existence and commercial importance of recombinant PH20. Production in animal cells, such as Chinese Hamster Ovary (CHO) cells, is a well-known method for producing biopharmaceuticals, especially when complex and human-like glycosylation is desired. The patent explicitly states that CHO cells are "particularly preferably" used for mass expression.
2. Impact of N-Glycosylation on Protein Activity and Side Effects: The patent acknowledges that recombinant PH20 proteins produced in insect cells and yeast "differ from human PH20 in terms of the pattern of N-glycosylation during post-translational modification, thus affecting the activity thereof and entailing the risk of side effects occurring in the body." [cite: "The recombinant PH20 proteins produced in insect cells and yeast differ from human PH20 in terms of the pattern of N-glycosylation during post-translational modification, thus affecting the activity thereof and entailing the risk of side effects occurring in the body."] It also states, "N-glycosylation may greatly affect the folding or activity of proteins". [cite: "N-glycosylation may greatly affect the folding or activity of proteins, and there is a very high possibility that the presence of glycosylation and the structure or form of glycans may vary depending on the host cell type, recombinant manipulation method, and culture conditions (Schilling, et al., 2002) when producing proteins or variants thereof present in nature using genetic engineering methods for industrial application."]
3. Role of Charge and Sialylation in Hyaluronidase Activity: Arming et al. (1997) revealed that "an arginine residue having positive charges in hyaluronidase PH20 is essential for enzymatic activity for binding to hyaluronic acid, which is a substrate having a large amount of negative charges distributed therein". [cite: "Arming et al. revealed that an arginine residue having positive charges in hyaluronidase PH20 is essential for enzymatic activity for binding to hyaluronic acid, which is a substrate having a large amount of negative charges distributed therein (Arming et al. 1997)."] The patent further infers that "the charge distribution of the N-glycan also affects such enzymatic activity." [cite: "Therefore, it can be inferred that the charge distribution of the N-glycan also affects such enzymatic activity."] Crucially, the patent states, "It is important to prove that when hyaluronic acid, which is a substrate having a large amount of negative charges, binds to a hyaluronidase, the level of negatively charged sialic-acid-capping sugars in the N-glycans, that is, the sialylation level, affects the formation of the enzyme-substrate complex or the progress of the enzymatic reaction. In order to limit the sialylation level, the transfer of sialic acid to the galactose residue should be limited, desialylation should be performed, or the galactosylation level should be limited." [cite: "It is important to prove that when hyaluronic acid, which is a substrate having a large amount of negative charges, binds to a hyaluronidase, the level of negatively charged sialic-acid-capping sugars in the N-glycans, that is, the sialylation level, affects the formation of the enzyme-substrate complex or the progress of the enzymatic reaction." and "In order to limit the sialylation level, the transfer of sialic acid to the galactose residue should be limited, desialylation should be performed, or the galactosylation level should be limited."] This provides a clear motivation to limit sialylation.
4. Influence of Culture Conditions on N-Glycosylation: The patent lists several culture conditions known to affect N-glycosylation, including "glucose or glutamine concentration in the culture medium (Tachibana et al. 1994), concentration of dissolved oxygen (DO) (Restelli et al. 2006), culture medium pH (Borys et al. 1993), concentration of ammonia of culture medium (Borys et al. 1994), culture temperature (Clark et al. 2004), and the like." [cite: "Culture conditions affecting N-glycosylation include glucose or glutamine concentration in the culture medium (Tachibana et al. 1994), concentration of dissolved oxygen (DO) (Restelli et al. 2006), culture medium pH (Borys et al. 1993), concentration of ammonia of culture medium (Borys et al. 1994), culture temperature (Clark et al. 2004), and the like."] Schilling et al. (2002) generally supports that glycosylation patterns can vary depending on host cell type, recombinant manipulation, and culture conditions. [cite: "N-glycosylation may greatly affect the folding or activity of proteins, and there is a very high possibility that the presence of glycosylation and the structure or form of glycans may vary depending on the host cell type, recombinant manipulation method, and culture conditions (Schilling, et al., 2002) when producing proteins or variants thereof present in nature using genetic engineering methods for industrial application."]

Obviousness Argument for Claims 1, 11, and 13

A person having ordinary skill in the art (PHOSITA) in the field of biopharmaceutical manufacturing, seeking to optimize recombinant hyaluronidase PH20 (rHuPH20) activity and productivity, would have found the claimed methods and products obvious in light of the cited prior art.

Motivation to Combine References:

The motivation stems from the recognized problems and existing knowledge:

• Need for improved rHuPH20: rHuPH20 is an important therapeutic agent (Bookbinder et al., 2006), but producing it with optimal activity and avoiding side effects due to aberrant glycosylation, especially from non-mammalian hosts, is a known challenge. [cite: 1, 2, 3, 4, "The recombinant PH20 proteins produced in insect cells and yeast differ from human PH20 in terms of the pattern of N-glycosylation during post-translational modification, thus affecting the activity thereof and entailing the risk of side effects occurring in the body."] Mammalian cells, particularly CHO cells, are a preferred expression system to achieve desired glycosylation patterns for biopharmaceuticals.
• Controlling N-glycosylation for activity: It was widely known that N-glycosylation significantly affects protein activity and folding (Schilling et al., 2002). [cite: "N-glycosylation may greatly affect the folding or activity of proteins, and there is a very high possibility that the presence of glycosylation and the structure or form of glycans may vary depending on the host cell type, recombinant manipulation method, and culture conditions (Schilling, et al., 2002) when producing proteins or variants thereof present in nature using genetic engineering methods for industrial application."]
• Specific desire to limit sialylation for hyaluronidase activity: Arming et al. (1997) highlighted the critical role of charge in PH20's interaction with the negatively charged hyaluronic acid substrate. [cite: "Arming et al. revealed that an arginine residue having positive charges in hyaluronidase PH20 is essential for enzymatic activity for binding to hyaluronic acid, which is a substrate having a large amount of negative charges distributed therein (Arming et al. 1997)."] The patent itself clearly articulates that the level of negatively charged sialic acid in N-glycans impacts enzyme-substrate complex formation and enzymatic reaction, and therefore, limiting sialylation is a desired goal to improve activity. [cite: "It is important to prove that when hyaluronic acid, which is a substrate having a large amount of negative charges, binds to a hyaluronidase, the level of negatively charged sialic-acid-capping sugars in the N-glycans, that is, the sialylation level, affects the formation of the enzyme-substrate complex or the progress of the enzymatic reaction." and "In order to limit the sialylation level, the transfer of sialic acid to the galactose residue should be limited, desialylation should be performed, or the galactosylation level should be limited."]
• Known methods to modulate N-glycosylation: The prior art unequivocally established that culture conditions, including temperature (Clark et al., 2004), glucose concentration (Tachibana et al., 1994), and pH (Borys et al., 1993), directly influence N-glycosylation patterns. [cite: "Culture conditions affecting N-glycosylation include glucose or glutamine concentration in the culture medium (Tachibana et al. 1994), concentration of dissolved oxygen (DO) (Restelli et al. 2006), culture medium pH (Borys et al. 1993), concentration of ammonia of culture medium (Borys et al. 1994), culture temperature (Clark et al. 2004), and the like."]

Obviousness of Claim 1 (Method Claim):

A PHOSITA, motivated to produce a more active rHuPH20 by limiting its sialylation, would have reasonably looked to manipulate known culture conditions, such as temperature, glucose concentration, and pH, which were already known to influence N-glycosylation. The two-step method described in Claim 1 – an initial culture phase at 35-38°C to a certain cell density, followed by a temperature shift to 28-34°C for an extended period (2-18 days), while simultaneously controlling residual glucose (0.001-4.5 g/L) or pH (6.8-7.2) – represents a combination of known techniques for optimizing recombinant protein production and glycosylation.

Temperature shifts, particularly lowering temperature during the production phase, are a common strategy in mammalian cell culture to reduce metabolic rate, increase cell viability, and improve recombinant protein yield and quality, including glycosylation. Similarly, controlling nutrient levels like glucose and maintaining pH are standard parameters adjusted in bioprocess optimization to impact cell metabolism and post-translational modifications. For instance, Aghamohseni et al. (2014) showed that reducing average culture pH resulted in lower growth but higher sialylation and galactosylation levels for a monoclonal antibody. Conversely, the patent aims for lower sialylation, and adjusting these parameters to achieve that specific outcome is within the realm of routine experimentation given the known effects.

Therefore, combining the teachings that: (1) rHuPH20 activity is linked to charge distribution and sialylation (Arming et al., 1997, and the patent's own problem statement) [cite: "Arming et al. revealed that an arginine residue having positive charges in hyaluronidase PH20 is essential for enzymatic activity for binding to hyaluronic acid, which is a substrate having a large amount of negative charges distributed therein (Arming et al. 1997). Therefore, it can be inferred that the charge distribution of the N-glycan also affects such enzymatic activity." and "It is important to prove that when hyaluronic acid, which is a substrate having a large amount of negative charges, binds to a hyaluronidase, the level of negatively charged sialic-acid-capping sugars in the N-glycans, that is, the sialylation level, affects the formation of the enzyme-substrate complex or the progress of the enzymatic reaction."], and (2) culture conditions like temperature, glucose, and pH modulate N-glycosylation (Tachibana et al., 1994; Borys et al., 1993; Clark et al., 2004) [cite: "Culture conditions affecting N-glycosylation include glucose or glutamine concentration in the culture medium (Tachibana et al. 1994), concentration of dissolved oxygen (DO) (Restelli et al. 2006), culture medium pH (Borys et al. 1993), concentration of ammonia of culture medium (Borys et al. 1994), culture temperature (Clark et al. 2004), and the like."], would have led a PHOSITA to the claimed method through predictable and routine experimentation. The specific numerical ranges for temperature, IVCD, culture duration, glucose concentration, and pH, while presented as optimal, would be discoverable through standard process development efforts, not requiring inventive ingenuity beyond what is taught in the prior art.

Obviousness of Claim 11 (Product-by-Process Claim):

If the method of Claim 1 is deemed obvious, then the hyaluronidase PH20 or variant produced by that method, as claimed in Claim 11, would also be obvious. The product's characteristic of a 1-38% sialylation content is directly achieved by the obvious method.

Obviousness of Claim 13 (Product Claim):

Claim 13 covers a hyaluronidase PH20 or variant defined by a sialylation content in its N-glycan of 1% to 38%. Given the clear motivation in the prior art to limit sialylation for improved hyaluronidase activity, a PHOSITA would have sought to produce such a molecule. The ability to control glycosylation through known culture parameters makes achieving a target sialylation range an expected outcome of optimization, rather than an unpredictable discovery. Therefore, the product itself, characterized by a specific range of sialylation to achieve a desired functional improvement that was motivated by the prior art, would be obvious. The "unexpectedly high levels" of activity claimed by the patent would need to be sufficiently striking and beyond the predictable range of optimization to overcome this obviousness challenge. However, the fundamental concept of modulating sialylation to affect enzyme activity was already understood. [cite: "Arming et al. revealed that an arginine residue having positive charges in hyaluronidase PH20 is essential for enzymatic activity for binding to hyaluronic acid, which is a substrate having a large amount of negative charges distributed therein (Arming et al. 1997). Therefore, it can be inferred that the charge distribution of the N-glycan also affects such enzymatic activity." and "It is important to prove that when hyaluronic acid, which is a substrate having a large amount of negative charges, binds to a hyaluronidase, the level of negatively charged sialic-acid-capping sugars in the N-glycans, that is, the sialylation level, affects the formation of the enzyme-substrate complex or the progress of the enzymatic reaction."]